Prostate Cancer Observation Varies With MRI, Genomic Testing Availability
Increasing adoption of prostate MRI and genomic testing may reduce overtreatment of prostate cancer, according to investigators.
Prostate Cancer News
PROSTATE CANCER ADVISOR
Prostate Cancer News
Apalutamide Improves rPFS in Metastatic Castration-Resistant Prostate Cancer
The median rPFS was 24.0 months in the apalutamide arm and 16.6 months in the placebo arm.
Breast, Prostate Cancer Common in Patients With COVID-19 and Cancer History
For patients hospitalized with COVID-19, prostate cancer was the most common cancer type across all databases.
Video May Aid in Precision Medicine for Prostate Cancer
In a study of men with prostate cancer or a family history of the disease, a higher proportion of men opted to view an educational video over personal genetic counseling prior to genetic testing.
Proteins May Predict Lethal Prostate Cancer in African-American Patients
The proteins were only predictive for African-American patients, not European-American patients.
Utilization Patterns Explain Nonadherence to Treatment for Multiple Myeloma, CML, Some Metastatic Cancers
A retrospective study of Medicare data showed a potential factor in nonadherence to oral cancer treatment regimens.
Study: 68Ga-PSMA-11 PET May Miss Pelvic Nodal Metastasis in Prostate Cancer
68Ga-PSMA-11 PET scans have a 40% sensitivity for detecting pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer, data show.
Surgery vs Radiation May Lower Risk of Death From High-Risk Prostate Cancer
In a large retrospective study, radical prostatectomy was significantly associated with a survival advantage among men with high-risk prostate cancer compared with external beam radiation therapy.
PSA Screening Recommendation Tied to Decrease in Prostate Cancer-Specific Survival
The 3-year prostate cancer-specific survival decreased significantly for insured patients.
How to Prevent a Cyberattack from Derailing Cancer Care
Cyberattacks on health care organizations may not be fully preventable, but there are ways to limit their impact on cancer care.
Androgen Signaling Inhibitors Appear More Effective in Luminal Metastatic Castration-Resistant Prostate Cancer
Patients with basal tumors did not derive a significant survival benefit from androgen signaling inhibitors.
Pembrolizumab and Olaparib Combination Therapy Shows Antitumor Activity and Acceptable Safety for Pretreated mCRPC
The nonrandomized, multicenter, multicohort, open-label, phase 1b/2 KEYNOTE-365 trial evaluated the safety, tolerability, and efficacy of pembrolizumab combination therapy in men with mCRPC.
Castration Resistance-Free Survival With Relugolix vs Leuprolide in Advanced Prostate Cancer
CRFS after relugolix was not significantly different compared with leuprolide in men with advanced prostate cancer and metastatic disease.
Androgen Deprivation Therapy Exposure Linked to Increased Risk of Dementia After Prostate Cancer
ADT exposure after prostate cancer treatment is associated with the onset of dementia.
Radiotherapy for Prostate Cancer Associated With Long-Term Complications
RT for prostate cancer is associated with distinct treatment-related complications such as cystitis and urinary stricture.
Real-World Apalutamide and Enzalutamide Rate of Treatment Discontinuation From AEs Higher Than in Clinical Trials for nmCRPC
Treatment discontinuation from adverse events in real-world use is 32% higher for apalutamide and 49% higher for enzalutamide than reported in clinical trials of patients with non-metastatic castration-resistant prostate cancer.
Abiraterone Added to ADT Improves Prostate Cancer Outcomes
Using abiraterone plus prednisolone with standard androgen deprivation therapy should be considered a new standard of care for patients with high-risk nonmetastatic prostate cancer, according to investigators.
Prostate Cancer Risk Up for World Trade Center Rescue Workers
The risk was most elevated for those to arrive earliest at the site.
Enzalutamide Plus ADT Prolongs Survival in Metastatic Hormone-Sensitive Prostate Cancer
Enzalutamide plus androgen deprivation therapy improved overall survival by 34%.
Prostate Cancer Screenings Fell Sharply Early in COVID-19 Pandemic
The decrease in prostate cancer screening rates was the smallest among 5 cancers studied.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...